SEHK:2171Biotechs
Is BCMA CAR-T Catalogue Inclusion And Pipeline Progress Altering The Investment Case For CARsgen (SEHK:2171)?
CARsgen Therapeutics Holdings recently reported that its BCMA-targeted CAR-T therapy zevorcabtagene autoleucel was added to China’s new Commercial Health Insurance Innovative Drug Catalogue, while early clinical data for its allogeneic BCMA CAR-T candidate CT0596 were presented at the 67th ASH Congress with favorable tolerability and efficacy signals.
Together, these updates underline CARsgen’s progress across both approved and next-generation BCMA therapies, signaling broader potential...